Patrick Duxbury

Of Counsel

Leader of Life Sciences (UK)

Birmingham

Qualified, Solicitor of England & Wales (1993)

patrick.duxbury@gowlingwlg.com

+44 (0)121 393 0212

+44 (0) 7818 003 973

Domaines de pratique

Bio

Patrick is ranked as the only 'Star Individual' for Life Sciences: Transactional in Chambers UK 2024, is ranked in the Hall of Fame in Legal 500 2025 for his work in Life Sciences and is ranked as an IP Star in the 2024 edition of Managing Intellectual Property.

Patrick is also ranked in the Who's Who Thought Leader for Life Sciences publication and received 'Life Sciences - Transactional Lawyer of the Year 2022' at the prestigious, international, Who's Who Legal Awards 2022. He has since been named in Who's Who Legal: Thought Leaders Global Elite 2024 for 'Life Sciences – Transactional', recognising him among the top 2% of all Who's Who Legal-recognised legal practitioners from around the world.

"Patrick Duxbury is known for his deft handling of complex technology transfer, research and collaboration agreements, indeed all manner of IP-driven transactions. A source says: 'He is a leading light and has made a considerable difference to the sector over may decades.' " Chambers UK 2020.

"They are very experienced and very committed. I feel like they are with us in the fight and they never let us down. With Gowling, they really care about getting you a great deal." Chambers 2024.

The Gowling WLG UK IP transaction team is ranked in the top tier by Chambers UK 2024. The team won the IP Transaction Team of the Year Award from MIP in 2018 and Life Sciences team of the year at the 2024 Legal Business Awards on the back of their work for AstraZeneca on its deal with Quell Therapeutics. The team was also highly recommended at the Legal Business Awards in 2021 for their work on the AZ/University of Oxford COVID-19 vaccine deal.

Expérience

Patrick has represented AstraZeneca on a large number of transactions over 20 years including, their landmark collaboration agreement for the development and distribution of the University of Oxford's potential COVID-19 vaccine. He also advised AstraZeneca on its $8 billion collaboration with Merck in the IO space and its two $6 billion deals with Daiichi Sankyo. Most recently he has advised AZ on their deals with Quell Therapeutics and with Pintetree Therapeutics.
Patrick advised BioNTech on its latest collaboration with Pfizer to co-develop and co-commercialise an mRNA shingles vaccine and has advised them on a number of other deals including licence and collaboration deals with Biotheus and its strategic collaboration with the UK Government to develop cancer vaccines.
Patrick worked with Cambridge Antibody Technology Group (and MedImmune) over 15 years on numerous business-critical licence and collaboration deals including transactions with Amgen, Dyax, Micromet, Wyeth and Merck. Patrick acted for MedImmune on its widely publicised in-licence of the Phase III antibody, Tremelimumab, from Pfizer and its five antibody product deal with Amgen.
Patrick advised Astex Therapeutics for many years and helped the company through all of its significant transactions, including its widely publicised licence and collaboration deals with AstraZeneca, Novartis ( which has resulted in the cancer drug Kisqali), J&J and GSK and its merger with SuperGen.
Patrick has worked with GSK, including on the creation of Convergence Pharmaceuticals and Autifony Therapeutics (both funded by SV Life Sciences) and Nerre Therapeutics. He also advised GSK on its 400 million Euro deal with MorphoSys.
Patrick has acted for Heptares (now Nxera Pharma) for many years on a range of transactions. These include its multi-million pound drug collaboration with Genentech in 2019, its strategic multi-target partnership with Takeda Pharmaceutical Company Limited (also in 2019), its $3.25 billion collaboration with Allergan and most recently its deals with, Genentech, GSK (2020), Neurocrine (2021) and BI (2024).
Patrick has acted for argenx BV on many of its significant partnering deals including with Leo, Abbvie and Shire.
Patrick advised Crescendo Biologics on its transaction with Takeda, a deal which won the Scrip licensing deal of the year for 2017.
Patrick also acts for a range of life science investors such as Epidarex and SROne.
Patrick advised Immunocore on its transaction with Genentech for a phase 1 ready asset.

Patrick Duxbury

Of Counsel

Bio

Bio

Expérience

Expérience

Qualifications

Qualifications

Carrière

Formation

Langues parlées

Gardez le contact

Patrick Duxbury

Of Counsel

Bio

Bio

Expérience

Expérience

Qualifications

Qualifications

Carrière

Formation

Langues parlées

Recevez nos mises à jour

Gardez le contact